This clinical trial is focused on studying a rare blood disorder called immune-mediated thrombotic thrombocytopenic purpura (iTTP). This condition involves the formation of small blood clots throughout the body, which can lead to a low platelet count and damage to organs. The study will explore the effectiveness and safety of a treatment using a medication called caplacizumab, in combination with immunosuppressive therapy. Immunosuppressive therapy is a treatment that helps reduce the activity of the immune system. The study will not use the usual first-line treatment known as therapeutic plasma exchange, which is a procedure that removes and replaces blood plasma.

The purpose of the study is to evaluate how well the combination of caplacizumab and immunosuppressive therapy works in treating adults with iTTP. Participants in the study will receive caplacizumab, which is given as an injection either into a vein (intravenous) or under the skin (subcutaneous). The study will monitor participants over a period of time to see if they achieve remission, which means the symptoms of iTTP improve or disappear without needing therapeutic plasma exchange. The study will also look at the occurrence of any side effects or adverse events during the treatment period.

Participants will be observed for their response to the treatment, including how quickly their platelet count returns to normal and whether they experience any relapses or worsening of their condition. The study aims to provide valuable information on the potential benefits of using caplacizumab and immunosuppressive therapy for treating iTTP, offering insights into alternative treatment options for this serious condition.